Phase IIa examination of the effect of oral dosing of NV-52 on surrogate markers of inflammatory bowel disease (IBD) in patients with stable disease but with a consistent abnormality in one or more surrogate marker.
Phase Ia Pharmacokinetic and Tolerability Study of Oral NV-27 in Normal Healthy Volunteers
Phase Ib Chronic Pharmacokinetic and Tolerability Study of Oral NV-52 in Normal Healthy Volunteers
100 Clinical Results associated with Kazia Research Pty Ltd.
0 Patents (Medical) associated with Kazia Research Pty Ltd.
100 Deals associated with Kazia Research Pty Ltd.
100 Translational Medicine associated with Kazia Research Pty Ltd.